Trial Profile

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eloralintide (Primary)
Indications Obesity
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

06 Nov 2025 According to a Eli Lilly and Company Media Release, results from the trial were presented at Obesity Week 2025 and simultaneously published in The Lancet.
06 Nov 2025 Primary endpoint has been met. (Percent Change from Baseline in Body Weight), according to a Eli Lilly and Company Media Release.
06 Nov 2025 Results presented in the Eli Lilly and Company Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com